I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Book ChapterDOI
Clinical Trials with Pseudomonas Exotoxin Immunotoxins
L. H. Pai,Ira Pastan +1 more
TL;DR: In summary, PE is a 613 amino acid single-chain protein secreted by Pseudomonas aeruginosa that catalyzes the ADP-ribosylation and inactivation of elongation factor 2 and thereby inhibits protein synthesis and leads to cell death.
Journal ArticleDOI
A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.
TL;DR: A novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain is described.
Journal ArticleDOI
Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin.
TL;DR: The data show that DNA immunization and antibody phage display may be useful in producing new rITs against hematologic malignancies and cytotoxicity was specific and CD30‐mediated.
Book ChapterDOI
Isolation and Characterization of the Human MDR (P-Glycoprotein) Genes
TL;DR: Most of the studies described in this chapter were carried out with a series of multidrug-resistant (MDR) derivatives of the human KB carcinoma cell line, which represent a subclone of human HeLa cells, as indicated by their karyotype and cell surface markers.
Journal ArticleDOI
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin Targeting Recombinant Immunotoxins
TL;DR: Data show that MSLN shedding is an impediment to the antitumor activity of SS1P and RG7787, and approaches that decrease MSLn shedding could enhance the efficacy of immunotoxins and immunoconjugates targeting MSlN-expressing tumors.